HRP20160356T1 - Kristalni solvati 6-(piperidin-4-iloksi)-2h-izokinolin-1-on hidroklorida - Google Patents

Kristalni solvati 6-(piperidin-4-iloksi)-2h-izokinolin-1-on hidroklorida Download PDF

Info

Publication number
HRP20160356T1
HRP20160356T1 HRP20160356TT HRP20160356T HRP20160356T1 HR P20160356 T1 HRP20160356 T1 HR P20160356T1 HR P20160356T T HRP20160356T T HR P20160356TT HR P20160356 T HRP20160356 T HR P20160356T HR P20160356 T1 HRP20160356 T1 HR P20160356T1
Authority
HR
Croatia
Prior art keywords
hydrate
nephropathy
isoquinolin
yloxy
piperidin
Prior art date
Application number
HRP20160356TT
Other languages
English (en)
Croatian (hr)
Inventor
Norbert Nagel
Bruno Baumgartner
Harald Berchtold
Oliver Plettenburg
Dieter Kadereit
Mandy MOHNICKE
Simon Gessler
Joachim TILLNER
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20160356T1 publication Critical patent/HRP20160356T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
HRP20160356TT 2011-07-08 2012-06-27 Kristalni solvati 6-(piperidin-4-iloksi)-2h-izokinolin-1-on hidroklorida HRP20160356T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11305890 2011-07-08
EP11306033 2011-12-29
PCT/EP2012/062431 WO2013007518A1 (en) 2011-07-08 2012-06-27 Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
EP12730523.3A EP2729460B1 (en) 2011-07-08 2012-06-27 Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride

Publications (1)

Publication Number Publication Date
HRP20160356T1 true HRP20160356T1 (hr) 2016-05-06

Family

ID=46397257

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160356TT HRP20160356T1 (hr) 2011-07-08 2012-06-27 Kristalni solvati 6-(piperidin-4-iloksi)-2h-izokinolin-1-on hidroklorida

Country Status (22)

Country Link
US (2) US8710078B2 (enExample)
EP (1) EP2729460B1 (enExample)
JP (1) JP6357100B2 (enExample)
KR (1) KR102013566B1 (enExample)
CN (1) CN103781778B (enExample)
AU (1) AU2012283276B2 (enExample)
CA (1) CA2843773C (enExample)
CO (1) CO6870040A2 (enExample)
CY (1) CY1118326T1 (enExample)
DK (1) DK2729460T3 (enExample)
ES (1) ES2568245T3 (enExample)
HR (1) HRP20160356T1 (enExample)
HU (1) HUE027309T2 (enExample)
IN (1) IN2014CN00817A (enExample)
MA (1) MA35340B1 (enExample)
PH (1) PH12014500289B1 (enExample)
PL (1) PL2729460T3 (enExample)
RU (1) RU2619129C2 (enExample)
SG (1) SG2014007520A (enExample)
SI (1) SI2729460T1 (enExample)
WO (1) WO2013007518A1 (enExample)
ZA (1) ZA201400941B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2729460T3 (en) * 2011-07-08 2016-04-18 Sanofi Sa Crystalline solvates of 6- (piperidin-4-yloxy) -2H-isoquinolin-1-one hydrochloride
KR20250036929A (ko) 2022-08-01 2025-03-14 발로 헬스, 인코포레이티드 6-치환된-1-(2h)-아이소퀴놀리논 및 중간체 화합물의 제조 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
PT1910333E (pt) * 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7478743B2 (en) 2006-02-28 2009-01-20 Holley Jr John M Carton for tapered and cylindrical articles
JP5421783B2 (ja) * 2006-12-27 2014-02-19 サノフイ Rhoキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体
ATE502027T1 (de) * 2006-12-27 2011-04-15 Sanofi Aventis Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
KR20100103646A (ko) * 2007-12-26 2010-09-27 사노피-아벤티스 6­치환된­1­(2h)­이소퀴놀리논의 제조 방법
DK2729460T3 (en) * 2011-07-08 2016-04-18 Sanofi Sa Crystalline solvates of 6- (piperidin-4-yloxy) -2H-isoquinolin-1-one hydrochloride

Also Published As

Publication number Publication date
WO2013007518A1 (en) 2013-01-17
PL2729460T3 (pl) 2016-07-29
CO6870040A2 (es) 2014-02-20
PH12014500289A1 (en) 2014-03-24
RU2014104358A (ru) 2015-08-20
MA35340B1 (fr) 2014-08-01
US20140221656A1 (en) 2014-08-07
AU2012283276A1 (en) 2014-02-27
CN103781778A (zh) 2014-05-07
CY1118326T1 (el) 2017-06-28
HK1192546A1 (zh) 2014-08-22
IN2014CN00817A (enExample) 2015-04-03
JP6357100B2 (ja) 2018-07-11
HUE027309T2 (en) 2016-10-28
CA2843773C (en) 2018-11-06
SI2729460T1 (sl) 2016-05-31
SG2014007520A (en) 2014-07-30
CA2843773A1 (en) 2013-01-17
KR102013566B1 (ko) 2019-08-23
PH12014500289B1 (en) 2019-06-28
NZ620864A (en) 2015-08-28
US20130012444A1 (en) 2013-01-10
DK2729460T3 (en) 2016-04-18
AU2012283276B2 (en) 2014-07-24
KR20140045550A (ko) 2014-04-16
EP2729460A1 (en) 2014-05-14
RU2619129C2 (ru) 2017-05-12
CN103781778B (zh) 2015-10-07
JP2014518235A (ja) 2014-07-28
ES2568245T3 (es) 2016-04-28
US8710078B2 (en) 2014-04-29
EP2729460B1 (en) 2016-01-13
ZA201400941B (en) 2015-05-27

Similar Documents

Publication Publication Date Title
JP2018507244A5 (enExample)
CN101658675A (zh) 含钙拮抗剂、ace抑制剂和他汀类药的药物组合物
JP2012236849A5 (enExample)
JP2013514986A5 (enExample)
JP2017528507A5 (enExample)
EA019471B1 (ru) Твердая фармацевтическая композиция, содержащая амлодипин и лозартан
TW200306799A (en) Combination of organic compounds
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
JP2010516700A5 (enExample)
JP2013518914A5 (enExample)
JP2006514611A5 (enExample)
AU2017203028A1 (en) Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors
JP2020524689A5 (enExample)
EA201401042A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
JP2016512234A (ja) 薬学的複合製剤
JP2009517411A5 (enExample)
TW201202255A (en) Novel composition for the prevention and/or treatment of thromboembolism
HRP20160358T1 (hr) Polimorfi 6-(piperidin-4-iloksi)-2h-izokinolin-1-on hidroklorida
EP1951309A2 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
WO2014058046A1 (ja) カルシウム拮抗薬/アンジオテンシンii受容体拮抗薬含有医薬製剤
CN101690816A (zh) 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
JP6151854B2 (ja) 心血管疾患の治療用経口製剤
JP6302802B2 (ja) カルシウム拮抗薬/アンジオテンシンii受容体拮抗薬含有医薬製剤の製造方法
RU2014104358A (ru) Кристаллические сольваты гидрохлорида 6-(пиперидин-4-илокси)-2н-изохинолин-1-oha
JP2007524699A5 (enExample)